Connecticut Ignored FDA Guidance and Scientific Evidence in Kratom Ban

By CT CannaTimes - 4.2.2026

Connecticut has moved to classify kratom; a natural plant used by thousands of residents…as a Schedule I controlled substance, placing it in the same legal category as heroin.

But a closer look at federal guidance and peer-reviewed science reveals a critical problem:

The state ignored clear distinctions between kratom leaf and a separate compound, 7-hydroxymitragynine (7-OH).

The Law Was Pre-Decided : But the Science Was Not

The Connecticut Department of Consumer Protection (DCP) openly acknowledged that its authority was limited:

“The Legislature decided that the Substances… shall be controlled substances… the Department does not have authority to leave the Substances unscheduled.”

That means the key decision—whether kratom should be controlled at all—was made before public input, scientific review, or regulatory nuance could meaningfully shape the outcome.

But even within that constraint, Connecticut still had a choice:

How to classify kratom vs. 7-OH

And this is where the state ignored both federal guidance and scientific evidence.

FDA: Kratom ≠ 7-OH (And the Distinction Matters)

In a 2025 federal communication, the U.S. Food and Drug Administration made a critical distinction:

“7-hydroxymitragynine is found in trace amounts in kratom leaf… our primary concern is concentrated 7-OH… this is an important distinction.”

That statement directly contradicts Connecticut’s approach of treating raw kratom plant material and concentrated 7-OH products as functionally the same.

The FDA has repeatedly emphasized:

• Natural kratom leaf contains only trace levels of 7-OH
• The real safety concerns involve concentrated or chemically modified products

Peer-Reviewed Science: “False and Misleading” Products Driving Risk

Scientific literature reinforces this distinction.

A major analytical study found:

Products marketed as “kratom extracts” often contained abnormally high levels of 7-hydroxymitragynine and lacked the natural alkaloid profile of kratom leaf, concluding that labeling them as “kratom” is “false and misleading.”

Another pharmacological review explained:

Traditional kratom contains only minimal exposure to 7-OH, while many modern products are chemically enriched or semi-synthetic derivatives marketed under the same name.

In plain terms:

The risk profile of raw kratom leaf and high-potency 7-OH products is not the same.

Connecticut Collapsed Two Different Things Into One Ban

Despite:

• FDA warnings distinguishing kratom from concentrated 7-OH

• Scientific evidence showing synthetic or enriched products drive most risks

• Public testimony overwhelmingly opposing kratom scheduling

Connecticut chose the most extreme option available:

Schedule I for everything — including raw plant material

DCP justified this by stating:

“There is no… approved medical use… [therefore] Schedule I”

But that logic has a major flaw:

• Lack of FDA approval ≠ same risk profile
• It does not justify treating a natural plant with centuries of use the same as concentrated opioid-like compounds

Public Input Overwhelmingly Opposed the Ban

The state received:

• 405 written comments
• 64 oral testimonies

The vast majority:

Opposed banning kratom

Many cited:

• Pain management
• Recovery from opioids and alcohol
• Functional daily use without impairment

Yet the final decision stated plainly:

“The Department will not revise the proposed regulation.”

A Policy Failure Rooted in Oversimplification

Connecticut had a scientifically defensible path:

• Schedule or restrict concentrated 7-OH products

• Regulate manufacturing and labeling

• Preserve access to raw kratom leaf

Instead, the state chose:

• A blanket Schedule I classification

• No differentiation between plant and synthetic compounds

• A policy misaligned with both federal guidance and scientific evidence

The Bottom Line

This is not a case of “following the science.”

It is a case of:

Collapsing complex pharmacology into a one-size-fits-all prohibition

When:

• The FDA says the distinction is “important”

• Scientists say misbranded products are the real issue

• Hundreds of residents oppose the ban

And the state still proceeds unchanged—

That is not evidence-based policy.

That is policy by mandate, not by science.